News
Thermosome Initiates Final Dose Level in Phase I Trial of Lead Compound THE001
— Independent Data Safety Monitoring Board declared dose level 2 as safe and recommended escalation to final dose level 3
Thermosome, a drug development company focused on targeted tumor therapies, today announced its ongoing Phase I trial has progressed to dose level 3 (DL3) after the independent Data Safety Monitoring Board (DSMB) declared dose level 2 (DL2) as safe and recommended escalation to the final dose level (DL3). In the trial, the Company’s lead compound THE001is tested in patients with heavily pre-treated, locally advanced unresectable or metastatic soft tissue sarcoma (STS) in combination with regional hyperthermia. Read more…
Thermosome Presents Encouraging Initial Clinical Data from Phase I Trial of Lead Compound THE001
— THE001 safe and well tolerated in first two dose level, demonstrating encouraging signs of clinical activity
— Data presented at The Connective Tissue Oncology Society (CTOS) Annual Meeting 2024
Thermosome, a drug development company focused on targeted tumor therapies, today announced encouraging initial clinical data from the ongoing Phase I study of its lead compound THE001 in patients with heavily pre-treated, locally advanced unresectable or metastatic soft tissue sarcoma (STS). The data were presented as a poster (#P410) titled “Phase I study of THE001 (DPPG2-TSL-DOX) combined with regional hyperthermia in patients with locally advanced or metastatic soft tissue sarcoma” at The Connective Tissue Oncology Society (CTOS) Annual Meeting 2024 in San Diego, USA. Read more…
Ebenbuild Appoints Charles A. Taylor, PhD as Chairman of the Board
— World renowned researcher and leader in predictive, simulation-based medicine to support further growth and strengthen footprint in the U.S.
Ebenbuild, a company developing personalized, AI-enabled digital twins of lungs to support clinical decisions and digital clinical trials, today announced that Charles A. Taylor, PhD has been appointed Chairman of the Board. Dr. Taylor is a pioneer in the field of predictive, simulation-based medicine where he applied computational fluid dynamics to predict outcomes of cardiovascular interventions in individual patients.
ANEUVO to Showcase Breakthrough Neuromodulation Device ExaStim® at MEDICA 2024
— Novel Device with FDA Breakthrough Device Designation to Treat Chronic Spinal Cord Injuries
— Attendees Invited to Visit Booth Hall 10 / H44 to Explore FDA Breakthrough Device Designation Technology
The next step in restoring mobility and independence for individuals with chronic spinal cord injuries is almost here. ANEUVO, a company dedicated to improving lives through innovative therapies, will showcase its ExaStim® Stimulation System (‘ExaStim’) at the MEDICA 2024 conference. ExaStim is a portable, customizable, non-invasive spinal cord stimulation solution designed to help people with chronic spinal cord injuries regain motor function. Read more…